Viking Therapeutics (VKTX) CEO Brian Lian Sells 148,517 Shares

What Happened

• Brian Lian, President & CEO and Director of Viking Therapeutics (VKTX), had 221,667 performance-based restricted stock units (RSUs) vest on July 28, 2026 (granted Jan 3, 2023). On July 29, 2026, 148,517 of the issued shares were sold in the open market for a weighted average price of $33.32, netting approximately $4,947,888. The shares sold were disposed of automatically to satisfy tax withholding obligations tied to the RSU issuance.

Key Details

• Award/Acquisition: 221,667 shares issued (vested) on 2026-07-28 (performance RSU; 33.33% tranche vested upon achievement of a non‑financial goal). Reported acquisition price: $0.00 (RSU vesting).
• Sale: 148,517 shares sold on 2026-07-29; weighted average price $33.32; total proceeds ≈ $4,947,888. Sale prices ranged from $32.82 to $33.77 across multiple trades.
• Reason for sale: Automatic, non‑discretionary sale solely to satisfy tax withholding on the vested RSUs (per filing footnote).
• Shares owned after transaction: Not specified in this Form 4 filing.
• Filing timeliness: Form 4 filed 2026-07-29 for transactions on 2026-07-28/29 — no late filing flag indicated.
• Footnote availability: The filer offers to provide a breakdown of the number of shares sold at each separate price on request.

Context

• This was not a voluntary opportunistic sale; the filing states the shares were sold automatically to cover tax obligations arising from RSU vesting. Such tax-withholding sales are common after equity awards and do not necessarily signal an independent decision to reduce holdings.